Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HRAS | P01112 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | LGALS2 | P05162 | 1/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370961 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL30685973 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL20741969 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL10708838 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL31396665 | 1.00 | SLC6A2 (0.56) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL6879915 | 0.95 | SLC6A2 (0.57) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL10588183 | 0.95 | SLC6A2 (0.57) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL11512380 | 0.93 | SLC6A2 (0.51) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL9791499 | 0.92 | SLC6A2 (0.60) | SLC6A2LGALS8PDE4DSLC5A2TSHR | |
| SCHEMBL8328411 | 0.92 | SLC6A2 (0.60) | SLC6A2LGALS8PDE4DSLC5A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960654-B2 | Method of forming glycosidic bonds from thioglycosides using an N,N-dialkylsulfinamide | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040019198-A1 | Method of forming glycosidic bonds from thioglycosides using an N,N-dialkylsulfinamide | CRICH DAVID C (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019198-A1 | Method of forming glycosidic bonds from thioglycosides using an N,N-dialkylsulfinamide | DDOST, STT3B, STT3A | SLC6A2 3916/4885LGALS8 190/4885PDE4D 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.